In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funds, enter strategic partnerships, receive FDA Breakthrough Device designation, and much more on the road to LSI Europe ‘25 in London (September 7-11).
Secured FDA Breakthrough Device designation for its novel room temperature machine perfusion (RTMP) platform for kidney preservation. The designation supports upcoming clinical studies and highlights the potential to improve transplant outcomes and reduce waitlist times.
Formed a strategic partnership with Elmstead Partners, bringing capital and life sciences expertise to support Cern’s women’s health innovation. The company’s microbicidal light-based device for treating both yeast and bacterial vaginosis is now in human clinical trials in the U.S.
Appointed Tzvika (Mike) Fisher as Chief Operations Officer to support operational scaling and global growth. His experience in strategic execution and complex production environments will help advance CorNeat Vision’s portfolio of ophthalmic devices addressing cornea, glaucoma, and ocular surface conditions.
Successfully completed ISO 13485 re-certification, reinforcing FeelTect’s commitment to quality and regulatory excellence. The milestone supports continued development of Tight Alright, the company’s connected-health device for improving compression therapy in venous leg ulcer care.
Appointed Ben Burnham as Chief Executive Officer, bringing over two decades of leadership experience across craniofacial, ENT, neurosurgery, and orthopedic medtech. His appointment comes at a key inflection point as ImmersiveTouch accelerates the adoption of its VR-based surgical planning platform and expands access to advanced visualization technologies.
Appointed Christopher Rowland as Board Chair, Dr. David Feigal as Head of Regulatory Affairs, and Joyce Peetermans as Acting CTO to strengthen leadership ahead of clinical trials. The additions bring decades of expertise in endoscopic innovation, FDA engagement, and medtech commercialization as Keyron advances its reversible, non-invasive ForePass device for obesity and diabetes.
Received a follow-on investment from Kindling Investment Partners to support its multimodal point-of-care diagnostic platform. MIMOSA’s AI-powered multimodal imaging technology is designed to improve diagnostic accuracy across all skin tones, addressing critical equity gaps in conditions like diabetic foot ulcers.
Announced $70 million in strategic capital commitments from Ligand and Medtronic, alongside an expanded partnership to develop AVIM-enabled leadless pacemakers. The company also closed public and private equity offerings and secured additional non-dilutive funding, bringing total proceeds to $111 million and extending cash runway into 2H 2027.
Joined the Board of Directors at RxSight, bringing decades of medtech leadership experience, including his role as Co-Founder and CEO of Axonics and recent exits at Axonics ($3.7B) and SoniVie ($600M). He currently serves on several boards and is a Venture Partner at Andera Partners and Sherpa Capital Partners.
Appointed Jason Webster as Head of Commercial Operations and Customer Success, strengthening its leadership team with 24 years of orthopedic experience at J&J, Biomet, and Zimmer Biomet. The hire supports Scalpel AI’s mission to scale safer, smarter, and greener surgical solutions powered by AI and sensor intelligence.
Formed a strategic partnership with Berg Capital Partners, where Berg will serve as Chief Financial Officer and capital markets advisor. Berg Capital Partners will provide financial leadership and investor outreach to support the company’s growth and commercialization strategy in coronary chronic total occlusion treatment.
Appointed Dr. Bill Hunter as Chairman of the Board to guide REGENERA™ and SOFTAG™ through regulatory processes for marketing approval and commercialization in the U.S. and Europe. Hunter brings over 30 years of medtech leadership, including developing one of the first drug-eluting coronary stents and founding Canary Medical.
Appointed Bas Nieuwenhuis as VP of Engineering to lead the scale-up of AlettaⓇ , its autonomous robotic phlebotomy device. Nieuwenhuis brings nearly 30 years of medtech and lab automation experience, including a decade leading the development of BD Kiestra’s lab automation platform.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy